IDYA vs. XENE, CPRX, SYRS, CUE, OSMT, RDY, SRPT, CTLT, ELAN, and ROIV
Should you be buying IDEAYA Biosciences stock or one of its competitors? The main competitors of IDEAYA Biosciences include Xenon Pharmaceuticals (XENE), Catalyst Pharmaceuticals (CPRX), Syros Pharmaceuticals (SYRS), Cue Biopharma (CUE), Osmotica Pharmaceuticals (OSMT), Dr. Reddy's Laboratories (RDY), Sarepta Therapeutics (SRPT), Catalent (CTLT), Elanco Animal Health (ELAN), and Roivant Sciences (ROIV). These companies are all part of the "medical" sector.
Xenon Pharmaceuticals (NASDAQ:XENE) and IDEAYA Biosciences (NASDAQ:IDYA) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, community ranking, earnings, profitability and analyst recommendations.
Xenon Pharmaceuticals has a net margin of 0.00% compared to Xenon Pharmaceuticals' net margin of -483.05%. Xenon Pharmaceuticals' return on equity of -20.09% beat IDEAYA Biosciences' return on equity.
Xenon Pharmaceuticals presently has a consensus target price of $59.11, suggesting a potential upside of 56.25%. IDEAYA Biosciences has a consensus target price of $48.27, suggesting a potential upside of 29.77%. Given IDEAYA Biosciences' higher probable upside, equities research analysts plainly believe Xenon Pharmaceuticals is more favorable than IDEAYA Biosciences.
95.5% of Xenon Pharmaceuticals shares are owned by institutional investors. Comparatively, 98.3% of IDEAYA Biosciences shares are owned by institutional investors. 5.5% of Xenon Pharmaceuticals shares are owned by insiders. Comparatively, 3.5% of IDEAYA Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
IDEAYA Biosciences has higher revenue and earnings than Xenon Pharmaceuticals. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Xenon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, Xenon Pharmaceuticals had 4 more articles in the media than IDEAYA Biosciences. MarketBeat recorded 8 mentions for Xenon Pharmaceuticals and 4 mentions for IDEAYA Biosciences. IDEAYA Biosciences' average media sentiment score of 1.15 beat Xenon Pharmaceuticals' score of 0.83 indicating that Xenon Pharmaceuticals is being referred to more favorably in the media.
Xenon Pharmaceuticals received 293 more outperform votes than IDEAYA Biosciences when rated by MarketBeat users. Likewise, 69.39% of users gave Xenon Pharmaceuticals an outperform vote while only 68.05% of users gave IDEAYA Biosciences an outperform vote.
Xenon Pharmaceuticals has a beta of 1.23, indicating that its stock price is 23% more volatile than the S&P 500. Comparatively, IDEAYA Biosciences has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500.
Summary
Xenon Pharmaceuticals beats IDEAYA Biosciences on 10 of the 17 factors compared between the two stocks.
Get IDEAYA Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for IDYA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IDYA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
IDEAYA Biosciences Competitors List
Related Companies and Tools
